Platelets are cytoplasmic fragments of megakaryocytes produced in the bone marrow. They have a diameter of approximately 2-3 µm and circulate in the blood of healthy individuals at concentrations ranging from 150,000 to 450,000/ µL. When an individual's blood platelet levels drop below 150,000/µL, a condition called thrombocytopenia, the risk of bleeding increases since platelets play a critical role in the maintenance of hemostasis. However, excessive or clinically significant bleeding usually does not occur until the platelet count drops below 30,000/µL. 1 Once thrombocytopenia develops, it is critical to determine the cause so the appropriate therapy can be instituted to restore platelet levels to normal. However, this can be a difficult task since there are many causes of thrombocytopenia. Causes of thrombocytopenia can be split into the following 2 major categories: reduced platelet production and increased platelet destruction. Platelet production disorders result from factors adversely affecting megakaryocyte production in the bone marrow. Increased platelet destruction can be caused by direct platelet cytotoxicity involving various drugs or other substances or, in the case of immune thrombocytopenias, by antibodymediated platelet destruction. Antibody-coated platelets are destroyed through the activation of complement, and also when blood circulates through the reticuloendothelial system (RES). Platelet antibodies react with specific glycoproteins (GPs) on the platelet surface. As antibody-sensitized platelets in the circulation pass through the spleen and liver of the RES, the fragment crystallizable (Fc) portion of the antibody molecules engage Fc-receptors on the surface of monocytes or macrophages in these organs, resulting in platelet clearance and destruction.
The 5 major immune thrombocytopenias for which platelet antibodies are tested in the clinical laboratory are: 1) autoimmune thrombocytopenia, which occurs when platelet autoantibodies form and cause destruction of the patient's own platelets; 1,2 2) drug-induced immune thrombocytopenia caused by autoantibodies that bind only to platelets in the presence of a drug that induced their production; 3,4 3) neonatal alloimmune thrombocytopenia (NAIT), in which maternal IgG alloantibodies produced against a paternal platelet-specific antigen on the fetal/infant's platelets cross the placenta enter fetal circulation, and destroy fetal and neonatal platelets; 5,6 4) posttransfusion purpura (PTP), a severe thrombocytopenic event that occurs when both allo-and auto-antibodies are produced following a blood transfusion; 7 and 5) multi-platelet transfusion refractoriness (MPTR), which develops when patients become immunized against human leukocyte antigen (HLA) and/or platelet-specific alloantigens following a blood or platelet transfusion, making it difficult to find compatible platelets for 8, 9 When an immune cause of platelet destruction is suspected, a direct test of the patient's platelets for antibodies and/or an indirect test for antibodies present in the plasma can help confirm a diagnosis.
This continuing education update will describe the various human platelet alloantigens (HPA) and the GPs expressing them, explain the most current assays used for platelet antibody detection and platelet antigen genotyping, and demonstrate the use of these tests in the laboratory diagnosis of immune platelet disorders using actual patient case studies.
Human Platelet Alloantigens
Platelets, like RBCs and neutrophils, have their own unique antigens expressed on the surface of the cell membrane. To date, 27 different HPA expressed on 5 different GPs have been described and named, and with 1 exception, all are the result of single nucleotide changes in the sequence of the coding genes (single nucleotide polymorphism [SNP] ), which result in single amino acid changes in the GPs ( Table 1 ). All are biallelic with the higher frequency alleles designated "a" and the lower frequency alleles "b." Human platelet alloantigens, for which antibodies against only 1 of the 2 antigens have been characterized, are labeled with a "w" for workshop. It is important to note that platelets also express other "non-HPA" antigens not listed in Table 1 that can elicit clinically significant antibodies (eg, GPIV [CD36], class I HLA, blood group ABH antigens). 9 An individual whose platelets lack an HPA can make antibodies against that antigen when they are exposed to platelets expressing it by transfusion or pregnancy. For instance, someone with the platelet type HPA-1b/1b has no HPA-1a form of GPIIb/IIIa on their platelets, but when exposed to platelets expressing HPA-1a can make HPA-1a-specific antibodies. If this occurs, the person is said to be "alloimmunized."
Platelet Autoantigens
Patients affected with idiopathic thrombocytopenic purpura (ITP) make autoantibodies 1,10 that, unlike the aforementioned alloantibodies (HPA-1a, HPA-2a), target common epitopes on various platelet GPs expressed by virtually everyone's platelets. Platelet glycoprotein complexes GPIIb/IIIa and GPIb/IX are the most frequent targets of autoantibodies and less often GPIa/ IIa. 11,12 Recent guidelines from the American Society of Hematology do not recommend testing for platelet autoantibodies as a useful guide in the diagnosis of ITP. 1,10 However, despite these recommendations, platelet antibody testing for ITP remains 1 of the most frequently ordered tests from our laboratory, and we find it is useful in helping to determine whether or not a patient has ITP in specific cases, especially when the test is positive. 12 Platelet autoantibodies are also produced by patients affected with PTP and MPTR. A direct testing of the patient's platelets for autoantibodies can be useful. However, this is not always fully appreciated since the focus is often on antibodies against platelet alloantigens that are also produced in these disorders.
Autoantibodies that require the presence of a specific drug in order to react with platelets are produced in the immune platelet disorder, "drug-induced immune thrombocytopenia." 3, 13, 14 Laboratory testing is available for the detection of drug-dependent antibodies, 15, 16 but the specifics will not be reviewed here and readers are referred to several review articles available on the subject. 3,4,13 
Platelet Antibody and Antigen Tests
Detection of platelet-specific antibodies against HPA in serum or autoantibodies on the patient's platelets provides important laboratory results that can aid in making a clinical diagnosis of an immune platelet disorder. Every 2 years large platelet antibody reference labs from all over the world participate in the International Platelet Immunology Workshop to establish best practices in platelet antibody and antigen testing. 17 Early on, this workshop determined that a thorough workup for platelet alloantibodies required the use of multiple test methods, including a glycoprotein-specific assay, a test employing intact/whole platelets, and HPA genotyping. 18 Glycoprotein-specific assays are important since they are the most sensitive and specific for identifying the HPA specificity of serum antibodies. 19 An assay using intact platelets is critical to back up the glycoprotein-specific tests since the process of platelet lysis with detergent used in those assays followed by capture of GP with a specific monoclonal antibody can interfere with detection of antibodies that can only be detected using whole platelets. Genotyping of patient DNA is often used to confirm HPA specificity of antibodies and for prenatal typing of a fetus in suspected cases of NAIT. 20
Intact Platelet Antibody Assay
Currently, 1 of the most commonly used assays for platelet antibody detection using intact/whole platelets is immunofluorescence detection by flow cytometry. 18,21,22 A typical assay involves incubating patient's serum with intact blood group O platelets, followed by washing away unbound antibody and detection of platelet-bound antibodies with fluorescent labeled anti-human immunoglobulin G (IgG) or immunoglobulin M (IgM) reagents by flow cytometry ( Figure  1) . 22 Flow cytometry has also been used successfully to detect autoantibodies in a direct assay of the patient's platelets. 23, 24 Although flow cytometry is a sensitive method, it has low specificity when non-HPA antibodies (eg, class I HLA or ABH antibodies) are also present in the serum since there is no way to differentiate them. If this is the case, additional testing is required using a glycoprotein-specific antigen capture assay (ACA).
Glycoprotein-specific Antigen Capture Assay
Glycoprotein-specific ACAs for platelet antibody detection are sandwich enzyme-linked immunosorbent assay (ELISA) tests involving the following: 1) capturing platelet GPs from detergent lysates of whole platelets using GPspecific monoclonal antibodies attached to a solid support (microtiter plate well or polystyrene bead); 2) detecting antibody bound to a specific HPA expressed on the captured GP using anti-human IgG with an enzyme tag; and 3) determining the antibody HPA specificity based on the pattern of reactivity obtained with a panel of HPA-typed platelets (Figure 2) . 22 The antigen capture ELISA (ACE), 25 modified antigen capture ELISA (MACE), 26 and monoclonal antibody immobilization of platelet antigens (MAIPA) 19 assay are 3 of the most popular glycoprotein-specific ACA in use ( Figure  2) . Antigen capture assays are very specific for determining antibodies targeting HPA (eg, HPA-1a, HPA-3b) present in a patient's serum as monoclonal antibody capture of platelet GPs excludes interference by non-HPA antibodies present. This is critical since a significant number of patient sera contain non-HPA antibodies. For example, as many as 38% of previously pregnant females have HLA class I antibodies in their sera. 27, 28 Antigen capture assays are also more specific for the detection of platelet autoantibodies. Autoantibodies can be eluted from the patient's washed platelets, and the eluate tested against the most common glycoprotein targets for autoantibodies. Patient's serum or plasma can also be tested in the same assay. 12
Platelet Genotyping Assay
Human platelet alloantigens expressed on an individual's platelets are determined by genotyping DNA for the SNPs (Table 1 ) encoding them. Multiple methods have been developed for HPA genotyping, and readers are encouraged to examine several detailed reviews on the subject. 22, 29, 30 Determining a patient's platelet genotype is helpful in confirming the HPA specificity of antibodies detected in the serum. For instance, if a patient has serum antibodies with apparent specificity for HPA-5a, then the patient would be expected to be homozygous for the HPA-5b allele and have the genotype HPA5b/5b. For women who have experienced pregnancies affected labmedicine.com by NAIT, platelet genotyping is also valuable for determining the HPA zygosity of the fathers and the fetus in subsequent pregnancies (see case study 1 in this article).
Applications of Platelet Antibody Test Results in the Laboratory Diagnosis of Immune Platelet Disorders
The following 2 patient case studies were actually referred for testing to the Platelet and Neutrophil Immunology Lab, BloodCenter of Wisconsin. Both demonstrate how platelet antibody and antigen testing is applied in helping to make a clinical diagnosis of immune thrombocytopenia.
CASE 1: Neonatal Alloimmune Thrombocytopenia

Clinical History
A 26-year-old G2P2 female had an uncomplicated fullterm first pregnancy resulting in a healthy infant. Her second pregnancy was also uncomplicated and full-term, resulting in the birth of an 8 lb 2 oz apparently healthy male infant. However, the infant bled profusely following circumcision on day 2 of life. The infant's blood count was normal except for platelets of only 5000/µL. A head scan revealed the infant had experienced 2 intracranial hemorrhages, and 1 was believed to have occurred antenatally. The infant received 2 random donor platelet transfusions that failed to sustain his platelet levels. Transfusion of washed maternal platelets, however, resulted in an increase in platelet count to 50,000/µL. His platelets eventually reached normal levels, and he was discharged from the hospital in good health.
Platelet Antibody and Genotyping Test Results
Strong positive IgG antibody reactions were detected in maternal serum by flow cytometry against both normal target platelets and the father's group O platelets, indicating the presence of platelet-reactive antibodies ( Table 2) . Additional testing of maternal serum by GPIIb/IIIa MACE showed strong positive reactions only against HPA-1a+ /3a+ platelets ( Table 2) . However, platelet genotyping of maternal DNA showed she was HPA-1b/1b, -3a/3a, indicating that she was only capable of making antibodies against HPA-1a and not HPA-3a; therefore, the antibodies detected in the MACE were specific for HPA-1a. The serologic results, together with the parental genotyping results showing that the mother and father are incompatible for HPA-1a (Table 2) , support a diagnosis of NAIT due to antibodies against HPA-1a. Genetic counseling of the parents should be provided prior to any future pregnancies. Since the father is heterozygous (HPA1a/1b) for HPA-1, there is a 50% chance that the fetus in a subsequent pregnancy will inherit HPA-1a and be affected with NAIT. As a result, prenatal genotyping for HPA-1a/1b of DNA from fetal amniocytes should be performed in all subsequent pregnancies. If the fetus is found to have inherited HPA-1a, then the mother can be treated with intravenous Figure 2_Diagram depicting Glycoprotein Antigen Capture ELISA Tests. Antigen Capture ELISA (ACE) involves addition of patient's serum to the well of a microtiter plate to which platelet GP have been captured by a specific mouse IgG monoclonal antibody. Plateletspecific antibodies in patient's serum (serum platelet Aby) bound to HPA on the GP are detected by addition of an enzyme-labeled goat anti-human IgG (Enz-anti-human IgG). A modification of the ACE is the modified antigen capture ELISA (MACE, not shown) in which the patient's serum is incubated with platelets first, platelets washed and lysed in detergent, and the platelet lysate added to the well for capture of platelet GP/serum platelet Aby complex by GP-specific monoclonal antibody. The MACE is performed to prevent false-positive results that can occur by ACE when anti-mouse IgG antibodies in patient's serum react with mouse IgG monoclonal antibodies adhered to the well. In the MACE these antibodies are removed when platelets are washed. The MAIPA assay is very similar to the MACE. In the MAIPA, platelets are incubated with patient's serum, washed, incubated with GP-specific monoclonal, washed again, and platelets lysed and the platelet GP/serum platelet Aby/monoclonal antibody complex is captured by goat anti-mouse IgG adhered to the bottom of the well. 
Case History
A 36-year-old G1P1 female presented with chronic fatigue, easy bruising, and some mucocutaneous bleeding. Her CBC was normal except for a platelet count of 10,000/ µL. She was taking no medications. She was treated with prednisone, and her platelet count increased to 100,000/µL. Blood samples were collected before treatment began and were submitted for platelet antibody testing. 
DNA Platelet Genotype
Mother: HPA-1b/1b, -2a/2a, -3a/3a, -4a/4a, -5a/5b, -6a/6a, -9a/9a, -15a/15b Father:
HPA-1a/1b, -2a/2a, -3a/3b, -4a/4a, -5a/5a, -6a/6a, -9a/9a, -15b/15b
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